In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Valvular Heart Disease II (VHDII) Survey

Valvular Heart Diseases

Valvular heart disease accounts for a significant part of cardiovascular disease. The purpose of a survey on valvular heart disease is to evaluate practices and show how physicians act in the diagnosis and management of their patients. The data resulting from this project will provide the basis for the improvement of practice guidelines, targeted educational programmes and new scientific evaluation. Participating hospitals will be able to compare their disease management procedures and outcomes with established guidelines and with the results of other hospitals in the same country, as well as in other countries

The roll-out of this survey during the first months of 2017 is timed to allow the release of the first results simultaneously with the publication of the 2017 ESC/EACTS guidelines on valvular heart disease. This evaluation of real-life practice will form an appropriate reference for targeted educational programmes, followed by subsequent surveys to assess their impact.



Objectives of the Registry

The main objective of the VHD II Survey is to:

  • Analyse existing practices in the management of patients with severe native heart valve disease or any previous transcatheter or surgical valvular intervention (referring modalities, investigations, indications for intervention, results of different techniques and their proportionate use).
  • Compare these practices with existing ESC guidelines.
  • Evaluate changes in practice since the first European survey on valvular disease that was performed in 2001.

Other objectives will consist of analyses of the data collected in the program, in order to report in-hospital and six-month mortality and morbidity after enrolment in the survey, according to the chosen management strategy. Specific issues and related questions to be addressed during the study on valvular heart disease will focus on:

  • The use of diagnostic procedures: echocardiography, stress tests, CT scan and cardiac magnetic resonance, invasive investigations.
  • The use and results of valve interventions: surgical valve replacement and repair, concomitant coronary or aortic surgery, transcatheter aortic or mitral valve surgery, percutaneous valvuloplasty.
  • The management of patients after a valve intervention: modalities of follow-up, antithrombotic therapy, other medical therapy.
  • Assessment of specific sub-groups of patients of interest, because of their increasing incidence: elderly patients, interventions in asymptomatic patients, heart failure patients and investigations used to detect coronary disease.

Characteristics of the Registry

The ESC Valvular Heart Disease II Survey is an international, prospective, longitudinal multicentre, observational study in worldwide countries.

Consenting patients who meet the eligibility criteria will be admitted consecutively to the study during a three-month period of recruitment, without any limit to the maximum number of patients included in a centre. Approximately five thousand patients will be enrolled overall.

A six-month follow-up assessment will be made by telephone or during a patient visit by the investigating centre.

Standard management of patients currently performed in routine clinical practice will be followed.  Drug prescriptions and indications to perform diagnostic/therapeutic procedures will be completely left to the participating cardiologists.

No specific protocols or recommendations for evaluation, management, and/or treatment will be put forth during this observational study.

All the 56 ESC country members are invited to participate in this survey through the National Cardiac Societies. A national coordinator is appointed for each country to manage the survey at national level.

If you are already registered as a participant in the EORP programme, you may connect to our secure website: http://www.eorp.org.

Registry Organisation

The Executive Committee of the registry is chaired by Bernard Iung.


 

Executive Committee

Alec Vahanian, Chair of EORP Oversight Committee, FR
Jeroen Bax, ESC President, NL
Susanna Price, GB
Victoria Delgado, NL
Michele De Bonis, IT
Bernard Prendergast, UK
Raphael Rosenheck, AT
Olaf Wendler, DE
Frank Ruschitzka, CH
Michael Haude, DE
Bogdan Popescu, RO
Stephan Windecker, CH
Gerhard Hindricks, DE
Luc Pierard, BE
Aldo Maggioni (ex-officio), EORP Scientific Coordinator, IT